

<p style="text-align: center;">Sun Pharmaceutical Industries Limited Regd. Office : Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390020 Corporate Office : Acme Plaza, Andheri-Kurla Road, Andheri (E), Mumbai - 400059 Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2011</p>						
	Quarter ended			Nine Months ended		Year ended
	31.12.2011	30.09.2011	31.12.2010	31.12.2011	31.12.2010	31.03.2011
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Net Sales / Income from Operations	63,121	56,478	44,727	171,718	143,438	193,312
Other Operating Income	38,064	37,387	30,231	109,628	85,801	117,158
Total Income	101,185	93,865	74,958	281,346	229,239	310,470
Expenditure						
(Increase) / Decrease in Stock in trade and work in progress	(1,266)	(1,689)	2,310	(3,995)	3,600	199
Consumption of Materials	25,170	22,435	12,396	67,922	50,610	71,826
Purchase of Traded Goods	4,886	4,352	5,012	13,502	13,715	17,668
Employees' Cost	8,086	7,869	6,313	23,803	19,067	26,109
Depreciation / Amortisation	1,985	1,813	1,820	5,557	4,840	6,423
Other Expenditure	21,798	19,244	16,575	57,209	45,078	62,544
Total Expenditure	60,659	54,024	44,426	163,998	136,910	184,769
Profit from Operations before Other Income, Interest & Tax	40,526	39,841	30,532	117,348	92,329	125,701
Other Income (net of mark to market loss on forward foreign exchange contracts)	(7,147)	1,342	1,051	(1,958)	5,483	7,108
Profit before Interest & Tax	33,379	41,183	31,583	115,390	97,812	132,809
Net Interest Income	3,631	4,357	3,858	12,107	8,701	12,593
Profit after Interest but before Tax	37,010	45,540	35,441	127,497	106,513	145,402
Tax Expense	487	1,785	1,174	4,899	5,411	7,022
Net Profit for the period from ordinary activities after tax	36,523	43,755	34,267	122,598	101,102	138,380
Paid-up Equity Share Capital						
Equity Shares - Face Value ₹ 1 each	10,356	10,356	10,356	10,356	10,356	10,356
Reserves excluding Revaluation Reserve						657,697
(As per last Audited Balance Sheet)						
Earnings Per Share of ₹ 1 each - in ` (Basic & Diluted)	3.5	4.2	3.3	11.8	9.8	13.4
Public Shareholding						
No. of Equity Shares of ₹ 1 each	375,753,755	375,753,755	375,751,755	375,753,755	375,751,755	375,753,755
Percentage of Shareholding	36.28	36.28	36.29	36.28	36.29	36.28
Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered						
No. of Equity Shares of ₹ 1 each	3,030,100	3,062,000	2,105,000	3,030,100	2,105,000	2,334,500
Percentage of Equity Shares (as a % of the total shareholding of promoters and promoter group)	0.46	0.46	0.32	0.46	0.32	0.35
Percentage of Equity Shares (as a % of the total share capital of the Company)	0.30	0.30	0.20	0.30	0.20	0.23
b) Non-encumbered						
No. of Equity Shares of ₹ 1 each	656,798,100	656,766,200	657,725,200	656,798,100	657,725,200	657,493,700
Percentage of Equity Shares (as a % of the total shareholding of promoters and promoter group)	99.54	99.54	99.68	99.54	99.68	99.65
Percentage of Equity Shares (as a % of the total share capital of the Company)	63.42	63.42	63.51	63.42	63.51	63.49
Research & Development Expenses incurred (included above)	4,565	4,320	3,697	12,813	11,840	15,728

Notes :

- The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 13, 2012 and have been subjected to a Limited Review by the Statutory Auditors of the Company.
- Other Operating Income represents Share of Income from Partnership Firms.
- The Company has only one reportable business segment namely 'Pharmaceuticals'.
- Tax Expense includes Current Tax and Deferred Tax.
- Status of investor complaints [in no.s] during the quarter, pursuant to clause 41 of the listing agreement :
Opening [0]; Received [7]; Resolved [7]; Closing [0].
- Figures for the previous period / year have been regrouped / reclassified, wherever considered necessary.

By order of the Board

Dilip S. Shanghvi
Chairman and Managing Director

Mumbai, February 13, 2012